7691-76-1 1-环丙基-2-(三苯基.膦亚基)乙酮

In other experiments, mice were serially treated with recombinant CCL2 (rCCL2) (10 µg/kg/every 3 days, i.p.), Toll-like receptor 4 (TLR4) specific ligand (lipopolysaccharide (LPS) -EB Ultrapure, 2 mg/kg/every 3 days, i.p.), LPS (2 mg/kg/every 3 days, i.p.; Solarbio), TLR4 inhibitor (TAK-242, 10 mg/kg/every 3 days, i.p.) or cyclooxygenase-2 (COX-2) inhibitor (Celecoxib, 10 mg/kg/every 2457 days, intragastric administration). Polyp or tumour load was determined as the sum of the size of all colon polyps/tumours presented per mouse. 来源文献：Yang Y, Li L, Xu C, Wang Y, Wang Z, Chen M, Jiang Z, Pan J, Yang C, Li X, Song K, Yan J, Xie W, Wu X, Chen Z,